We evaluated the effects of an EZH2 degrader on seven lymphoma cell lines and observed significant reductions in cell viability compared to EZH2 inhibitor, particularly in Burkitt’s lymphoma cell lines. This evidence concerns the gene EZH2 and lymphoma.